Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for Prevention of Preterm Neonatal Sepsis
NCT02954926Phase 3Completed
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of immune globulin in neonatal sepsis (2 arms), sponsored by Hormozgan University of Medical Sciences. Primary endpoint: Mortality at 7 days. Started Nov 2015; status: completed.
02
Drugs
immune globulin
03
Conditions
neonatal sepsis
Beyond the preview
Go deeper on NCT02954926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954926.